---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-114571"
form_type: "8-K"
ticker: "PCRX"
cik: "0001396814"
company_name: "Pacira BioSciences, Inc."
filed_at: "2026-10-08T13:24:36+00:00"
generated_at: "2026-10-12T15:35:09.624725+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Viatris to acquire Pacira BioSciences for $36.50/share cash, $1.65B equity value

## Summary
- Viatris agreed to acquire Pacira for $36.50/share in cash, aggregate equity value $1.65B; tender offer to commence within 15 business days.
- Pacira generated approximately $746M total revenue and approximately $177M adjusted EBITDA for the last twelve months ended June 30, 2026.
- Deal adds EXPAREL (bupivacaine liposome) and ZILRETTA (triamcinolone acetonide) non-opioid pain products; expected close by end of 2026.
- Viatris expects immediate accretion to guidance metrics; funded primarily from excess cash with remainder short-term borrowings; minimal impact on gross leverage ratio.
- Pacira would pay $62.0M termination fee if it accepts a superior offer; merger under Delaware Section 251(h), no shareholder vote required.

## SEC filing metadata
- accession: 0001104659-26-114571
- form_type: 8-K
- ticker: PCRX
- cik: 0001396814
- company_name: Pacira BioSciences, Inc.
- filed_at: 2026-10-08T13:24:36+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1396814/000110465926114571/0001104659-26-114571-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1396814/000110465926114571/tm2627240d2_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-114571
- JSON: https://secwatch.observer/filing/0001104659-26-114571.json
- Plain text: https://secwatch.observer/filing/0001104659-26-114571.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.